Latest News by Industry
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Blueprint Medicines Corp. (BPMC) on Thursday reported a loss of $50 million in its second quarter.
The Cambridge, Massachusetts-based company said it had a loss of 80 cents per share.
The results exceeded Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of $1.28 per share.
The cancer drug developer posted revenue of $138.2 million in the period, also beating Street forecasts. Nine analysts surveyed by Zacks expected $104.6 million.
Blueprint Medicines shares have increased 17% since the beginning of the year. The stock has climbed 64% in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BPMC at https://www.zacks.com/ap/BPMC